Serpin A-7 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Thyroxine-binding globulin (Serpin A-7, SERPINA7; UniProt P05543) expressed in HEK293 cells. Suited for antibody validation, binding studies, and plasma proteomics reference standards.
Expression system
HEK293
Cat. #
REC-SerpinA7

In stock

SKU
REC-SerpinA7
$498.00

Target Overview

Serpin A-7, encoded by SERPINA7, is the principal thyroid hormone transport protein in human serum. A secreted glycoprotein of 415 amino acids (UniProt P05543), it belongs to the serine protease inhibitor (serpin) superfamily but functions primarily as a carrier protein rather than a classical protease inhibitor, binding thyroxine (T4) and, with lower affinity, triiodothyronine (T3) to regulate their bioavailability in circulation. This recombinant form is produced in HEK293 mammalian cells, which supports the native N-linked glycosylation patterns important for correct folding and hormone-binding capacity — features that prokaryotic expression systems do not reliably reproduce for this target. The full-length mature sequence (415 residues) is expressed to provide a structurally representative antigen and functional standard. Researchers use this recombinant in several contexts. It serves as a positive-control antigen for validating anti-SERPINA7 antibodies by Western blot and ELISA, including confirmation of expected molecular weight under reducing and non-reducing conditions. In binding and competition assays, it provides a defined protein source for measuring T4 association constants or for assessing the impact of SERPINA7 point mutations on ligand affinity. In plasma proteomics workflows — where SERPINA7 signal is used as an abundance reference in longitudinal sample sets — a recombinant standard with confirmed identity simplifies inter-run normalisation. The protein is also used in structural studies examining serpin-family conformational dynamics. Researchers validating anti-Serpin A-7 antibodies with this recombinant can pair it with the Triple Point Biologics matched antibody (SKU: RP-SerpinA7), available separately on this site.

Background

SERPINA7 encodes Thyroxine-binding globulin (TBG), a ~54 kDa secreted glycoprotein synthesised predominantly in the liver and released into the bloodstream, where it accounts for approximately 75% of circulating thyroxine (T4) transport. As a member of the serpin superfamily, TBG shares the characteristic tertiary fold of this protein family — a central beta-sheet A flanked by alpha helices — but has evolved a high-affinity T4-binding site in place of the reactive-centre loop that drives protease inhibition in classical serpins. This structural adaptation makes SERPINA7 a biochemically distinctive serpin and an informative model for studying serpin conformational plasticity. Inherited variants in SERPINA7 are studied as molecular determinants of TBG excess, partial deficiency, and complete deficiency (TBG-CD) — conditions that alter total thyroid hormone measurements without necessarily reflecting true changes in free hormone levels or thyroid function. Gawandi et al. (2026, PMID 41882709) reported recurrent pathogenic SERPINA7 mutations associated with TBG-CD coexisting with hypothyroidism in Indian pedigrees, coupling pedigree analysis with in silico structural modelling of mutant TBG — work that illustrates how recombinant wild-type and variant proteins are used to benchmark computational predictions against biochemical phenotype. A related case report by the same group (PMID 41675115) documented concurrent TBG excess and congenital hypothyroidism, highlighting the interpretive complexity that SERPINA7 variants introduce to thyroid function panel results. Beyond thyroid physiology, SERPINA7 has been identified as a differentially abundant protein in plasma proteomics studies of diverse clinical phenotypes. Wu et al. (2026, PMID 42176864) detected SERPINA7 as part of a longitudinal plasma protein signature in lung cancer patients undergoing radiation therapy, and Starodubtseva et al. (2026, PMID 42196175) identified it in a first-trimester proteomic profiling study of fetal growth disorders — illustrating how SERPINA7 abundance in plasma serves as a detectable analyte in broad discovery proteomics contexts. Yang et al. (2026, PMID 42318010) similarly observed SERPINA7 among proteins reprogrammed in a lung proteome dataset. In the research setting, recombinant Serpin A-7 produced in HEK293 cells provides a characterised, mammalian-glycosylated reference protein for immunoassay development, antibody specificity testing, structural biology, and proteomics standardisation. Its role as a constitutively secreted, abundant serum carrier protein makes it a tractable target for validating detection reagents in complex biological matrices.

Applications

  • Antibody validation by Western blot using recombinant Serpin A-7 as a positive control antigen (pair with matched antibody SKU: RP-SerpinA7)
  • ELISA standard curve generation for quantification of TBG in human serum or plasma samples
  • Thyroxine (T4) binding and competition assays to characterise ligand-binding affinity of wild-type and variant TBG
  • Mutant vs. wild-type Serpin A-7 comparative binding studies to assess impact of SERPINA7 point mutations on hormone transport capacity
  • Proteomics reference standard for SERPINA7 peptide identification and signal normalisation in longitudinal plasma proteomics experiments
  • Immunogen validation confirming antibody epitope accessibility under reducing and non-reducing SDS-PAGE conditions
  • Serpin-family conformational dynamics studies (e.g., latent-state conversion, loop-sheet insertion assays) using TBG as a non-inhibitory serpin model

References

  1. Gawandi S et al. Identification of recurrent pathogenic SERPINA7 mutation causing coexistence of TBG-CD and hypothyroidism in Indian pedigrees: in Silico structural analysis of mutant TBG and literature reappraisal. Thyroid Res. 2026. doi:10.1186/s13044-026-00287-6. PMID: 41882709
  2. Gawandi S et al. Co-existence of Congenital Hypothyroidism (CH) and TBG-Excess in a Boy Causing Simultaneous Elevation in Thyroid Stimulating Hormone (TSH) and Thyroxine (T4) Levels: First Report from India and Review of the Literature. Indian J Clin Biochem. 2026. doi:10.1007/s12291-024-01190-3. PMID: 41675115
  3. Wu L et al. Longitudinal Plasma Proteomics Reveals an Immuno-thrombotic Signature That Predicts Radiation Pneumonitis in Lung Cancer. Int J Radiat Oncol Biol Phys. 2026. doi:10.1016/j.ijrobp.2026.05.018. PMID: 42176864
  4. Starodubtseva N et al. Integrated Clinical and Molecular Profiling of Fetal Growth Disorders in the First Trimester. Int J Mol Sci. 2026. doi:10.3390/ijms27104192. PMID: 42196175
  5. Yang H et al. Millettia speciosa reprograms the lung proteome and suppresses CCL24-driven eosinophilic inflammation in allergic asthma. Front Allergy. 2026. doi:10.3389/falgy.2026.1726706. PMID: 42318010

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; blood plasma

Frequently Asked Questions

What is the expected molecular weight of recombinant Serpin A-7 on SDS-PAGE and Western blot?

The mature Serpin A-7 polypeptide is 415 amino acids, giving a predicted unglycosylated MW of approximately 46 kDa. Because this recombinant is expressed in HEK293 cells and carries native-like N-linked glycosylation, the apparent MW on reducing SDS-PAGE typically runs between 54–60 kDa — a shift of roughly 8–14 kDa attributable to glycan addition. Expect a single diffuse band in that range; heterogeneous glycosylation accounts for slight band broadening. Deglycosylation with PNGase F collapses the band to ~46 kDa, which can serve as a useful confirmation step.

Is recombinant Serpin A-7 a classical serine protease inhibitor or purely a carrier protein — does it have inhibitory activity?

Serpin A-7 (Thyroxine-Binding Globulin, TBG) is structurally a serpin but is not a functional serine protease inhibitor under physiological conditions. Its reactive-center loop does not efficiently form stable acyl-enzyme complexes with canonical serpin targets. Its primary role is high-affinity binding of thyroxine (T4, Kd ~10⁻¹⁰ M) and, with roughly 10-fold lower affinity, T3. This recombinant is therefore appropriate for hormone-binding assays, carrier-protein functional studies, and antibody validation — not for classical serpin inhibitory activity assays such as elastase or thrombin inhibition.

How do I set up a T4 hormone-binding assay using recombinant Serpin A-7, and what starting concentration is recommended?

For equilibrium binding or competitive displacement assays using radiolabeled or fluorescent T4 analogs, a starting concentration of 50–200 nM recombinant Serpin A-7 in binding buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% BSA) is a practical starting range. Binding reactions are typically equilibrated at 37°C for 30–60 minutes. Because T4 binding is strongly pH-sensitive (affinity drops sharply below pH 7.0), maintain buffer pH carefully. Include a no-protein background control and a known T4 standard curve. Confirm protein concentration by A280 or BCA before each assay run.

What buffer conditions are optimal for storing and diluting recombinant Serpin A-7 to preserve T4-binding activity?

This recombinant is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — conditions compatible with direct use in most binding and immunoassay formats. For T4-binding experiments, dilute into assay buffer (50 mM Tris-HCl pH 7.4–7.5, 150 mM NaCl, 0.1% BSA) rather than PBS alone; BSA reduces non-specific T4 adsorption to tube walls. Avoid Tween-20 concentrations above 0.05%, which can disrupt hydrophobic hormone interactions. Working dilutions are stable at 4°C for up to 48 hours; do not refreeze working stocks.

Can I use recombinant Serpin A-7 as a Western blot positive control with the matched anti-Serpin A-7 antibody RP-SerpinA7?

Yes — this is one of the primary intended uses. RP-SerpinA7 (/anti-serpin-a7-rabbit-polyclonal-antibody) was raised and validated against the same full-length mature sequence expressed here, so antigen–antibody compatibility is confirmed. Load 20–50 ng of recombinant Serpin A-7 per lane alongside your cell lysate or serum samples. Under reducing conditions, expect a band at 54–60 kDa. This loading range produces a clean signal without saturation at typical primary antibody dilutions of 1:500–1:2,000. Running the recombinant in an adjacent lane removes ambiguity about band identity in complex samples.

How much recombinant Serpin A-7 should I load for Western blot to avoid signal saturation with RP-SerpinA7 antibody?

For routine positive-control lanes, 25–50 ng per lane is a reliable starting point when using RP-SerpinA7 at 1:1,000 dilution with standard HRP-conjugated secondary antibodies and ECL detection. If you are running a dilution series to bracket dynamic range, test 10, 25, 50, and 100 ng. At 100 ng, some saturation is possible with highly sensitive detection substrates. Because the recombinant runs at 54–60 kDa (glycosylated), confirm band position matches your experimental sample before interpreting results from cell lines with differing glycosylation states.

How should I handle, aliquot, and store recombinant Serpin A-7 to maximize shelf life?

Upon receipt, spin briefly at 400 × g to collect any condensate, then aliquot into single-use volumes before the first freeze. Store at −20°C; avoid repeated freeze-thaw cycles, which progressively reduce both protein integrity and T4-binding capacity. Purity is >90–95% by SDS-PAGE, and endotoxin is <0.1 EU/µg by LAL assay. Properly stored aliquots are stable for at least 12 months. Do not store working dilutions long-term — prepare fresh from frozen stock for each experiment. Adding carrier BSA (0.1%) to diluted working stocks can reduce adsorptive losses when working at sub-nanomolar concentrations.

Why use HEK293-expressed recombinant Serpin A-7 instead of E. coli-expressed protein for functional assays?

Serpin A-7 carries multiple N-linked glycosylation sites that contribute to correct folding and full hormone-binding capacity. Prokaryotic expression systems lack the glycosylation machinery to reproduce this, and bacterially expressed TBG frequently exhibits reduced T4-binding affinity and aggregation propensity. HEK293 expression yields a glycoprotein with glycan patterns close to the endogenous serum protein, making this recombinant a more reliable functional standard for binding assays and a more structurally representative antigen for antibody validation by ELISA or Western blot.

Validation imagery coming soon

Western blot validation figures for REC-SerpinA7 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →